Kurzfassung

A Multicenter, Randomized, Parallel-group, Double-blind,
Two-arm, Phase III Study to Evaluate the Safety and Efficacy of
Anifrolumab Compared with Placebo in Male and Female
Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis.